Simeprevir/pegylated interferon/ribavirin triple therapy for recurrent hepatitis C after living donor liver transplantation

Publisher： John Wiley & Sons Inc

E-ISSN： 1872-034x|46|11|1118-1128

ISSN： 1386-6346

Source： HEPATOLOGY RESEARCH, Vol.46, Iss.11, 2016-10, pp. : 1118-1128

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Use of simeprevir following pre‐emptive pegylated interferon/ribavirin treatment for recurrent hepatitis C in living donor liver transplant recipients: a 12‐week pilot study

By  

JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES, Vol. 22, Iss. 2, 2015-02 ,pp. : 144-150

John Wiley & Sons Inc

Access to resources Recommend Favorite

Add‐on effects of fluvastatin in simeprevir/pegylated‐interferon/ribavirin combination therapy for patients with genotype 1 hepatitis C virus infection: A randomized controlled study

By  

HEPATOLOGY RESEARCH, Vol. 48, Iss. 3, 2018-02 ,pp. : E146-E154

John Wiley & Sons Inc

Access to resources Recommend Favorite

Randomized study comparing vitamin D3 and 1α‐Hydroxyvitamin D3 in combination with pegylated interferon/ribavirin therapy for chronic hepatitis C

By  

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, Vol. 30, Iss. 9, 2015-09 ,pp. : 1384-1390

John Wiley & Sons Inc

Access to resources Recommend Favorite

Achievement of Sustained Viral Response after Switching Treatment from Pegylated Interferon α-2b to α-2a and Ribavirin in Patients with Recurrence of Hepatitis C Virus Genotype 1 Infection after Liver Transplantation: A Case Report

By  

Intervirology, Vol. 55, Iss. 4, 2011-08 ,pp. : 306-310

Karger

Access to resources Recommend Favorite

Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant

By  

HEPATOLOGY, Vol. 61, Iss. 6, 2015-06 ,pp. : 1880-1886

John Wiley & Sons Inc

Access to resources Recommend Favorite